These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer. Martin GA; Chen AH; Parikh K Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177 [TBL] [Abstract][Full Text] [Related]
27. The emerging role of PARP inhibitors in prostate cancer. Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032 [TBL] [Abstract][Full Text] [Related]
31. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer. Castro E; Mateo J; Olmos D; de Bono JS Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330 [TBL] [Abstract][Full Text] [Related]
32. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology. Ziadeh T; Kourie HR Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995 [TBL] [Abstract][Full Text] [Related]
33. Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC). Xu C; Mao S; Jiang H Methods Mol Biol; 2020; 2204():75-89. PubMed ID: 32710316 [TBL] [Abstract][Full Text] [Related]
34. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618 [TBL] [Abstract][Full Text] [Related]
35. Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer. Mouw KW; Choudhury AD Cancer Treat Res; 2023; 186():103-124. PubMed ID: 37978133 [TBL] [Abstract][Full Text] [Related]
36. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? Catalano M; Lapucci A; Nobili S; De Gennaro Aquino I; Vascotto IA; Antonuzzo L; Villari D; Nesi G; Mini E; Roviello G Cancer Chemother Pharmacol; 2024 Jan; 93(1):1-9. PubMed ID: 37934252 [TBL] [Abstract][Full Text] [Related]
37. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369 [No Abstract] [Full Text] [Related]
38. How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients. Sciarra A; Frisenda M; Bevilacqua G; Gentilucci A; Cattarino S; Mariotti G; Del Giudice F; Di Pierro GB; Viscuso P; Casale P; Chung BI; Autorino R; Crivellaro S; Salciccia S Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614122 [TBL] [Abstract][Full Text] [Related]
39. Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients. Jiang X; Hu X; Gu Y; Li Y; Jin M; Zhao H; Gao R; Huang Z; Lu J Pathol Res Pract; 2021 Aug; 224():153507. PubMed ID: 34102435 [TBL] [Abstract][Full Text] [Related]
40. Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency. Zaman N; Kushwah AS; Badriprasad A; Chakraborty G Int Rev Cell Mol Biol; 2024; 389():257-301. PubMed ID: 39396849 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]